
Opinion|Videos|November 2, 2026
MuSK+ Subgroup -- RCP and OLP Results
Author(s)Suraj Muley, MD, FAAN, FRCP, FACP
Dr. Muley covers the MuSK-positive subgroup: 48 patients randomized, 46 entered the OLP, 44 completed 26 weeks.
Advertisement
Episodes in this series

Dr. Muley covers the MuSK-positive subgroup: 48 patients randomized, 46 entered the OLP, 44 completed 26 weeks. RCP results: MG-ADL reduction 4.1 (inebilizumab) vs. 3.1 (placebo); QMG reduction 5.0 vs. 4.2. At 52 weeks (26 weeks into OLP): MG-ADL 5.6 (ineb/ineb) and 5.1 (pbo/ineb); QMG 6.1 and 7.4. He notes this is a descriptive, non-statistical analysis but highlights the clinical significance of benefit in a distinct, often more severe subpopulation.
Advertisement
Related to this article

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.

Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.

Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is National Epilepsy Awareness Month!

Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Gefurulimab for Generalized Myasthenia Gravis
2
Phase 3 NIMBLE Trial: Cemdisiran Efficacy and Safety Results in gMG
3
FDA Requires NAION Warning Across GLP-1 Receptor Agonist Class
4
Myelin Repair Research in MS: Lessons From Clinical Trials and the Road Ahead
5


